We use cookies to understand how visitors search for and consume the information we provide, so that we can improve their experience. By browsing this website, you indicate your acceptance of the use of such cookiesAcceptRead more

Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Our products& pipeline
    • Diseases we target
    • GS010 for LHON
    • GS030 for Retinitis Pigmentosa
    • GS030 for Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
  • Investors& media
    • Company Overview
    • Press releases
    • Events & presentations
    • Stock information
    • Governance
    • Documentation

Product candidates

15 February 2021

GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs

22 Feb 2021 - 25 Feb 2021

4th Annual Gene Therapy for Rare Disorders – virtual

18 Feb 2021

OIS Gene Therapy Innovation Showcase – virtual

06 Feb 2021 - 07 Feb 2021

44th Annual Macula Society Meeting – Virtual

04 February 2021

GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non Human Primates

13 January 2021

GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®

20 Feb 2021 - 23 Feb 2021

47th NANOS Annual Meeting – Virtual Meeting

10 December 2020

GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine

13 Nov 2020 - 15 Nov 2020

American Academy of Ophthalmology 2020 – Virtual

03 November 2020

GenSight Biologics reports validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 10
  • View next 9 articles
© 2021 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
Go back to the page of the page